Modeling and Simulation - PK/PD Archives | Page 8 of 37 | サターラ

Poster

Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors

Certara2019年5月2日

Poster

Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models

Certara2019年4月22日

Poster

Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients

Certara2019年4月22日

Poster

Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies

Certara2019年4月22日

Poster

Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation

Certara2019年4月22日

On-Demand Webinar

How to Perform IVIVC for Extremely Long Acting Drugs

Watch this webinar to learn how to use in vitro and in vivo models to…

Certara2019年2月22日

Poster

Automated Average Bioequivalence Analysis with Additional Metrics and Statistics to Meet the FDA Guidance on Methylphenidate Hydrochloride Using Phoenix WinNonlin

Certara2018年11月4日

On-Demand Webinar

How to Use a Reference-scaled Average Bioequivalence Approach for Narrow Therapeutic Index Drugs

Watch this webinar to learn how RSABE for NTIDs can be performed in Phoenix WinNonlin…

Certara2018年9月25日

Brochure

Certara Professional Certification Program

Certara Professional Certification is an online accreditation of user competency and proficiency in analysis of…

Certara2018年8月21日

On-Demand Webinar

Using IVIVC to Optimize Your Drug Formulation After a Failed BA/BE Study

This webinar introduced how IVIVC can be used to get your drug program back on…

Certara2018年7月18日

© 2025 Certara. All Rights Reserved. | 個人情報保護

Powered by Translations.com GlobalLink Web Software